Business
Warrant Extension
Warrant Extension.
About this update from Incanthera Plc
[{"type":"text","content":"\n\n \n21 August 2023\nIncanthera plc\n(\"Incanthera\" or the \"Company\")\nWarrant Extension\nIncanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in dermatology and oncology announces the extension of the term of the Warrant Instrument issued to ImmuPharma plc. \n \n \nAmendment to Warrant Instrument\n \nOn 26 February 2020, prior to the Company's admission to the AQSE Growth Market, the Company entered into a warrant agreement with ImmuPharma plc entitling ImmuPharma plc to subscribe for 7,272,740 ordinary shares (\"Warrants\") at an exercise price of £0.095 per ordinary share valid until 06 September 2023\n \nAs per the Company's announcement of 13 March 2023 in which the Company announced it had agreed to vary the terms of certain warrants issued in conjunction with a placing, the board of the Company has also proposed extending the exercise period of the Warrants by one year in order to treat ImmuPharma plc on the same basis. The exercise price remains unchanged as at the point of issue.\n \nThe Warrants were originally valid until 06 September 2023 exercisable at £0.095. The term of the Warrants has now been extended to 06 September 2024 still exercisable at a price of £0.095.\n \nThe variation of the terms of the Warrants constitutes a related party transaction pursuant to Rule 4.6 of the AQSE Growth Market Access Rulebook (the \"Transaction\"). The Directors of the Company independent of the Transaction confirm that, having exercised reasonable care, skill and diligence, the related party transaction is fair and reasonable insofar as the shareholders of Incanthera are concerned.\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).\n \n \nFor further enquiries:\n \nIncanthera plc:\n \nwww.incanthera.com\n \nSimon Ward, Chief Executive Officer [email protected] +44 (0) 7747 625506 \n \nSuzanne Brocks, He...